Aflibercept news

All news on Aflibercept (also known as Eylea and Zaltrap): plants, production capacities, investments and involved companies.

30 April 2026

Roche to present ophthalmology portfolio data at ARVO 2026

ARVO 2026: real‑world data show Vabysmo reduces retinal fluid in nAMD/DME; Susvimo enables sustained delivery with lower treatment burden; early vamikibart IL‑6 results; 45+ abstracts.
29 April 2026

Genentech to present ophthalmology data at ARVO 2026

ARVO presentations: real-world Vabysmo data show retinal drying in wet AMD/DME; Susvimo demonstrates sustained delivery and reduced treatment burden; vamikibart shows early efficacy; >45 abstracts
2 April 2026

Merck starts pivotal Phase 2b/3 trial of MK-8748 (Tiespectus) for neovascular AMD

Pivotal Phase 2b/3 MALBEC trial begins for a bispecific Tie2 agonist/VEGF inhibitor in neovascular AMD; randomized vs aflibercept, primary endpoint mean BCVA change at Year 1.

Who will be producing Aflibercept in the future?

Find out with chemXplore Alpha

Learn more